Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer

Keyphrases

• Localized Prostate Cancer 100%
• Biological Effects 100%
• Imatinib Mesylate 100%
• Oligonucleotide Array 100%
• Adjuvant Imatinib 100%
• Immunohistochemistry 60%
• RNA Amplification 40%
• Laser Capture Microdissection 40%
• Microarray Data 40%
• Prostatectomy Specimen 40%
• MKP-1 40%
• Apoptosis 20%
• In Cancer 20%
• Cell Apoptosis 20%
• Microarray 20%
• Differential Expression 20%
• High-grade Prostate Cancer 20%
• Intermediate Risk 20%
• Gene Expression Changes 20%
• Neoadjuvant 20%
• Protein Expression 20%
• Targeted Therapy 20%
• Targeted Treatment 20%
• Biological Activity 20%
• Vascular Endothelial Cells 20%
• Microarray Analysis 20%
• Neoadjuvant Therapy 20%
• Systemic Treatment 20%
• Heterogeneous Tumors 20%
• Global Gene Expression 20%
• Long Genes 20%
• Clinical Activity 20%
• Frozen Tissue 20%
• Gene Set Enrichment Analysis 20%
• CD31 20%
• Gene Expression Differences 20%
• Antineoplastic Drugs 20%
• Point Following 20%
• Gene Expression Variability 20%
• Biological Variability 20%
• Ultrasound-guided Biopsy 20%

Medicine and Dentistry

• Prostate Cancer 100%
• Imatinib 100%
• Oligonucleotide 100%
• Biological Activity 100%
• Gene Expression 80%
• Immunohistochemistry 60%
• Prostatectomy 40%
• Programmed Cell Death 40%
• Targeted Therapy 40%
• Biopsy Technique 40%
• Laser Capture Microdissection 40%
• Malignant Neoplasm 20%
• Neoplasm 20%
• Endothelial Cell 20%
• Protein Expression 20%
• Systemic Therapy 20%
• Anticarcinogen 20%
• Neoadjuvant Therapy 20%
• Microarray Analysis 20%
• Genome-Wide Analysis of Gene Expression 20%
• Oral 20%